Results 21 to 30 of about 31,699 (207)

Pulmonary Pharmacokinetic and Pharmacodynamic Evaluation of Ampicillin/Sulbactam Regimens for Pneumonia Caused by Various Bacteria, including Acinetobacter baumannii

Antibiotics, 2023
This study aimed to assess the dosing regimens of ampicillin/sulbactam for pneumonia based on pulmonary pharmacokinetic (PK)/pharmacodynamic (PD) target attainment.
Tetsushu Onita, Kazuro Ikawa, Noriyuki Ishihara, Hiroki Tamaki, Takahisa Yano, Kohji Naora, Norifumi Morikawa   +6 more
doaj   +1 more source

High-dose Sulbactam Treatment for Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant [PDF]

Korean Journal of Critical Care Medicine, 2016
Background Several antibiotics can be used to treat ventilator-associated pneumonia caused by carbapenem-resistant A. baumannii (CRAB-VAP) including high-dose sulbactam. However, the effectiveness of high-dose sulbactam therapy is not well known.
In Beom Jeong, Moon Jun Na, Ji Woong Son, Do Yeon Jo, Sun Jung Kwon   +4 more
doaj   +1 more source

Alteration of adeS Contributes to Tigecycline Resistance and Collateral Sensitivity to Sulbactam in Acinetobacter baumannii

Microbiology Spectrum, 2023
The treatment of extensively drug-resistant (XDR) A. baumannii has emerged as a major problem. Tigecycline (TGC) and sulbactam (SUL) are both effective antibiotics against XDR A. baumannii.
Yunxing Yang, Xiaochen Liu, Danyan Zhou, Jintao He, Qiong Chen, Qingye Xu, Shenghai Wu, Weiying Zhang, Yue Yao, Ying Fu, Xiaoting Hua, Yunsong Yu, Xianjun Wang   +12 more
doaj   +1 more source

A green approach to the analysis of co-administered ampicillin/sulbactam and paracetamol in human urine

Acta Pharmaceutica, 2022
The novelty of this work is the simultaneous analysis of sulbactam (SUL), ampicillin (AMP), and paracetamol (PARA) in human urine samples, using the environmentally benign RP-HPLC method.
SELIM BASMA M., ABDELSALAM RANDA A., EL-GINDY ALAA, EID BASMA G., NEAMATALLAH THIKRYAT, KHAYYAT AHDAB N., HADAD GHADA M., ELKHOUDARY MAHMOUD M.   +7 more
doaj   +1 more source

Cefotaxime/sulbactam: clinical and pharmacological characteristics [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2019
The recently approved cefotaxime/sulbactam, combination of third-generation cephalosporin (cefotaxime) and beta-lactamase inhibitor (sulbactam), can combat resistance mechanisms associated with the production of serine beta-lactamases, including some ...
Ortenberg E.A., Golub A.V.
doaj   +1 more source

Effects of amikacin, polymyxin-B, and sulbactam combination on the pharmacodynamic indices of mutant selection against multi-drug resistant Acinetobacter baumannii

Frontiers in Microbiology, 2022
Amikacin and polymyxins as monotherapies are ineffective against multidrug-resistant Acinetobacter baumannii at the clinical dose. When polymyxins, aminoglycosides, and sulbactam are co-administered, the combinations exhibit in vitro synergistic ...
Shixing Zhu, Chu Song, Jiayuan Zhang, Shuo Diao, Tobias M. Heinrichs, Frederico S. Martins, Zhihua Lv, Zhihua Lv, Yuanqi Zhu, Mingming Yu, Mingming Yu, Sherwin K. B. Sy   +11 more
doaj   +1 more source

Observation of substrate diffusion and ligand binding in enzyme crystals using high-repetition-rate mix-and-inject serial crystallography

IUCrJ, 2021
Here, we illustrate what happens inside the catalytic cleft of an enzyme when substrate or ligand binds on single-millisecond timescales. The initial phase of the enzymatic cycle is observed with near-atomic resolution using the most advanced X-ray ...
Suraj Pandey, George Calvey, Andrea M. Katz, Tek Narsingh Malla, Faisal H. M. Koua, Jose M. Martin-Garcia, Ishwor Poudyal, Jay-How Yang, Mohammad Vakili, Oleksandr Yefanov, Kara A. Zielinski, Sasa Bajt, Salah Awel, Katarina Doerner, Matthias Frank, Luca Gelisio, Rebecca Jernigan, Henry Kirkwood, Marco Kloos, Jayanath Koliyadu, Valerio Mariani, Mitchell D. Miller, Grant Mills, Garrett Nelson, Jose L. Olmos Jr, Alireza Sadri, Tokushi Sato, Alexandra Tolstikova, Weijun Xu, Abbas Ourmazd, John C. H. Spence, Peter Schwander, Anton Barty, Henry N. Chapman, Petra Fromme, Adrian P. Mancuso, George N. Phillips Jr, Richard Bean, Lois Pollack, Marius Schmidt   +39 more
doaj   +1 more source

In vitro synergism of combinations of colistin with selected antibiotics against colistin-resistant Acinetobacter baumannii

GMS Hygiene and Infection Control, 2014
[english] Aim: The in vitro activity of colistin in combination with sulbactam, netilmicin, and vancomycin against colistin-resistant strains was investigated. Furthermore, the clonal relationship of the strains was analyzed.
Percin, Duygu, Akyol, Selcan, Kalin, Gamze   +2 more
doaj   +1 more source

Antibiofilm Activity of β-Lactam/β-Lactamase Inhibitor Combination against Multidrug-Resistant Salmonella Typhimurium

Pathogens, 2022
This study was designed to assess the effect of β-lactam/β-lactamase inhibitor combinations on the inhibition of biofilm formation of Salmonella Typhimurium.
Nana Nguefang Laure, Juhee Ahn
doaj   +1 more source

Sulbactam-containing β-lactamase inhibitor combinations [PDF]

, 2008
Sulbactam irreversibly inhibits the hydrolytic activity of β-lactamases. This compound is commercially available in combination with either ampicillin or cefoperazone. In each instance, the activity of the partner antibiotic against β-lactamase-producing
Sierra Valverde, Álvaro Javier, Akova, M.   +1 more
core   +1 more source